Candel Therapeutics, Inc.

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing off-the-shelf viral immunotherapies to combat cancer. Headquartered in Needham, Massachusetts, the company's core mission is to induce an individualized, systemic anti-tumor immune response to help patients fight various forms of cancer.

The company leverages two primary clinical-stage multimodal biological immunotherapy platforms: an adenovirus-based platform and a herpes simplex virus (HSV)-based platform. Its lead product candidates include CAN-2409, derived from the adenovirus platform, which is in late-stage clinical trials for prostate cancer, non-small cell lung cancer, and pancreatic cancer. The HSV-based platform's lead candidate, CAN-3110, is currently in Phase 1b clinical trials for recurrent high-grade glioma. Candel Therapeutics also utilizes its enLIGHTEN™ Discovery Platform to develop next-generation viral immunotherapies for solid tumors.

Recent notable developments include a commercialization agreement with EVERSANA in April 2026 to support the potential U.S. launch of aglatimagene besadenovec (CAN-2409) for localized prostate cancer, with a Biologics License Application (BLA) submission planned for Q4 2026. The company also reported extended survival data from its CAN-2409 trial in advanced non-small cell lung cancer in March 2026. Candel Therapeutics operates as a publicly traded entity on NASDAQ under the ticker symbol CADL, with Paul Peter Tak, M.D., Ph.D., FMedSci, serving as its President and CEO.